NASDAQ: IKT - Inhibikase Therapeutics, Inc.

Rentabilité sur six mois: -30.14%
Rendement en dividendes: 0%
Secteur: Healthcare

Calendrier des promotions Inhibikase Therapeutics, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc.

plus de détails
has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2020-12-23
ISIN US45719W1062
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.inhibikase.com
Цена ао 1.77
Changement de prix par jour: 0% (2.04)
Changement de prix par semaine: +10.87% (1.84)
Changement de prix par mois: -9.33% (2.25)
Changement de prix sur 3 mois: -12.82% (2.34)
Changement de prix sur six mois: -30.14% (2.92)
Changement de prix par an: +12.71% (1.81)
Evolution du prix sur 3 ans: +142.86% (0.84)
Evolution des prix depuis le début de l'année: -37.23% (3.25)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 25.18 1
P/BV 0.8124 9
P/E 0 0
EV/EBITDA -0.7235 0
Total: 3.88

Efficacité

Nom Signification Grade
ROA, % -48.66 0
ROE, % -52 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.0039 10
Total: 9.4

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -76.32 0
Rentabilité Ebitda, % 921.04 10
Rentabilité EPS, % -44.73 0
Total: 6
Plus de détails

Établissements Volume Partager, %
Armistice Capital, LLC 186046 3.01
Vanguard Group Inc 87447 1.42
Blair (William) & Company, L.L.C. 59375 0.96
Geode Capital Management, LLC 28692 0.46
Redmond Asset Management, LLC 20977 0.34
Edgewood Management Llc 16666 0.27
Renaissance Technologies, LLC 16122 0.26
State Street Corporation 10084 0.16
Tower Research Capital LLC (TRC) 2200 0.04
Morgan Stanley 1667 0.03



Superviseur Titre d'emploi Paiement Année de naissance
Dr. Milton H. Werner Ph.D. CEO, President & Director 697.96k 1964 (61 année)
Dr. Surendra Singh Head of Chemistry, Manufacturing & Controls N/A
Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D. CEO of Clintrex Research Corporation & Member of Scientific Advisory Board N/A
Dan Williams Controller N/A
Mr. Garth Lees-Rolfe CPA Chief Financial Officer N/A 1985 (40 années)

Adresse: United States, Atlanta. GA, 3350 Riverwood Parkway SE - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.inhibikase.com